Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: biowa who wrote (550)	4/25/2000 12:01:00 PM
From: jayhawk969	Respond to of 666

Biowa, Very good research. J.D.

To: biowa who wrote (550)	4/25/2000 12:05:00 PM
From: Micawber	Read Replies (1) \| Respond to of 666

Biowa: Thanks for the response. I hope that more details are released soon. Since the re-acquistion was possibly due to SKB's non-action, that of course begs the question as to why SKB didn't start construction. Market of course is selling first, asking questions later.

To: biowa who wrote (550)	4/25/2000 2:34:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 666

biowa, There is a clause that if SKB doesn't begin "construction" of a European manufacturing facility for the radio-labelled pdt, CLTR can reacquire the European rights Nice find. However, under the agreement, only the European rights would revert - the rest-of-the-world only reverts if SB in addition declares it's not intending to "develop and commercialize" outside Europe. So I think we really are looking at a conscious decision by SKB not to market and develop the drug outside the US. On the other hand, by the joint marketing agreement they indirectly gave us some reassurance that their US commitment is continuing. The most positive viewpoint is that it is something local to SKB non-US marketing plans - they don't seem to have much of an oncology presence - Hycamtin, a second-line ovarian drug, is all I saw in addition to granisetron, their anti-nauseau drug. Getting less favorable, another possibility is that they saw European approval as difficult and/or expensive - after all the stuff admits to being radioactive and probably kills butterflies as well. <g> (Outside Europe and Japan is likely a bust for this drug anyway - it probably needs to be locally manufactured because of its radioactive nature, and I can't see them setting up lots of plants all over the world.) The worst slant (but less likely in my view) is that they see a limited market size or problems getting approval for reasons not exclusively related to Europe. A skeptic would say they know a lot more about the drug than we do, and just how long does it take to "simply reformat" anyhow? Bottom line: I'm still holding a smallish stake, and will likely buy more on any further decline. Peter